| Literature DB >> 27699078 |
Maria Angela Guzzardi1, Patricia Iozzo1, Minna K Salonen2, Eero Kajantie3, Riikka Airaksinen4, Hannu Kiviranta4, Panu Rantakokko4, Johan Gunnar Eriksson5.
Abstract
As the population ages, the occurrence of chronic pathologies becomes more common. Leukocyte telomere shortening associates to ageing and age-related diseases. Recent studies suggest that environmental chemicals can affect telomere length. Persistent organic pollutants (POPs) are most relevant, since they are ingested with foods, and accumulate in the body for a long time. This longitudinal study was undertaken to test if circulating POPs predict telomere length and shortening in elderly people. We studied 1082 subjects belonging to the Helsinki Birth Cohort Study (born 1934-1944), undergoing two visits (2001-2004 and 2011-2014). POPs (oxychlordane, trans-nonachlor, p, p'-DDE, PCB 153, BDE 47, BDE 153) were analysed at baseline. Relative telomere length was measured twice, '10 years apart, by quantitative real-time PCR. Oxychlordane, trans-nonachlor and PCB-153 levels were significant predictors of telomere length and shortening. In men, we did not find a linear relationship between POPs exposure and telomere shortening. In women, a significant reduction across quartiles categories of oxychlordane and trans-nonachlor exposure was observed. Baseline characteristics of subjects in the highest POPs categories included higher levels of C-reactive protein and fasting glucose, and lower body fat percentage. This is one of few studies combining POPs and telomere length. Our results indicate that exposure to oxychlordane, trans-nonachlor and PCB 153 predicts telomere attrition. This finding is important because concentrations of POPs observed here occur in contemporary younger people, and may contribute to an accelerated ageing.Entities:
Keywords: aging; environmental chemicals; pops; telomere length
Year: 2016 PMID: 27699078 PMCID: PMC5036950 DOI: 10.14336/AD.2016.0209
Source DB: PubMed Journal: Aging Dis ISSN: 2152-5250 Impact factor: 6.745
Figure 1.Study design, showing the size of the population and the times of screening (left) and the predictive and outcome variables (right boxes). We hypothesized that serum POPs levels would associate with telomere shortening, affecting telomere length in 10 years.
Clinical characteristics of the study cohort
| All | Men | Women | p | |
|---|---|---|---|---|
| Age (yrs) | 71.0±0.1 | 70.8±0.1 | 71.1±0.1 | 0.218 |
| Body mass index (kg/m2) | 27.1±0.1 | 26.8±0.2 | 27.3±0.2 | 0.236 |
| Height (cm) | 168.3±0.3 | 176.2±0.3 | 162.2±0.2 | <0.001 |
| Waist-to-hip ratio | 0.97±0.08 | 0.96±0.00 | 0.97±0.00 | 0.080 |
| Lean body mass (kg) | 53.5±10.6 | 63.2±0.4 | 46.1±0.2 | <0.001 |
| Body fat (%) | 29.9±0.3 | 23.6±0.3 | 34.8±0.3 | <0.001 |
| Systolic BP | 151.5±0.6 | 151.3±0.9 | 151.8±0.9 | 0.714 |
| Diastolic BP | 83.9±0.3 | 84.8±0.5 | 83.1±0.4 | 0.005 |
| Mean BP | 106.6±0.4 | 108.0±0.5 | 105.5±0.5 | 0.001 |
| Total cholesterol (mmol/l) | 5.39±0.03 | 5.10±0.05 | 5.62±0.04 | <0.001 |
| HDL (mmol/l) | 1.62±0.01 | 1.46±0.01 | 1.74±0.01 | <0.001 |
| LDL (mmol/l) | 3.21±0.03 | 3.06±0.04 | 3.32±0.03 | <0.001 |
| Triglyceride (mmol/l) | 1.28±0.02 | 1.29±0.03 | 1.27±0.02 | 0.747 |
| Telomere length (T/S) | 0.855±0.009 | 0.807±0.012 | 0.893±0.013 | <0.001 |
| Oxychlordane (pg/ml) | 43.8±0.6 | 48.3±1.0 | 40.4±0.8 | <0.001 |
| Trans-nonachlor (pg/ml) | 114.7±2.0 | 136.1±3.3 | 98.1±2.2 | <0.001 |
| PCB 153 (pg/ml) | 1103.6±15.1 | 1264.1±25.1 | 979.2±16.8 | <0.001 |
| p,p'-DDE (pg/ml) | 2078.5±50.4 | 2072.7±66.8 | 2083.0±72.9 | 0.304 |
| BDE 47 (pg/ml) | 34.9±9.7 | 28.9±6.3 | 39.5±16.5 | 0.061 |
| BDE 153 (pg/ml) | 11.1±2.5 | 10.3±0.6 | 11.8±4.4 | <0.001 |
| Oxychlordane (pg/mg of lipids) | 12.6±0.2 | 13.9±0.3 | 11.5±0.2 | <0.001 |
| Trans-nonachlor (pg/mg of lipids) | 32.9±0.5 | 39.4±0.9 | 27.9±0.6 | <0.001 |
| PCB 153 (pg/mg of lipids) | 319±4 | 367±8 | 282±5 | <0.001 |
| p,p'-DDE (pg/mg of lipids) | 598±15 | 602±20 | 596±21 | 0.303 |
| BDE 47 (pg/mg of lipids) | 10.1±2.8 | 8.1±1.7 | 11.6±4.7 | 0.065 |
| BDE 153 (pg/mg of lipids) | 3.2±0.3 | 2.9±0.1 | 3.4±1.3 | <0.001 |
Data are presented as means±SEM.
Clinical data refer to the last visit, and POPs levels refer to the baseline visit. Telomere length measurements were available in 1077 subjects, serum lipids in 1080, POPs in 1076, and body composition data by bioimpedance in 1059 subjects.
Relationships between serum POPs levels and telomere shortening (n=1047) or telomere length at 10 years (n=1071)
| Serum POPs levels | Telomere shortening (Δ in 10 years)
| Telomere length (at 10 years)
| Adjustment (multivariate) | ||
|---|---|---|---|---|---|
| r | r | ||||
| Cumulative POPs levels | -0.069 | -0.093 | |||
| -0.050 | 0.109 | -0.082 | Lipids | ||
| -0.052 | 0.091 | -0.090 | Lipids + Δ Age | ||
| -0.033 | 0.299 | -0.070 | Lipids + Body Fat % | ||
| -0.035 | 0.267 | -0.074 | Lipids + Δ Age + Body Fat % | ||
| -0.031 | 0.326 | -0.061 | Lipids+ Δ Age + Body Fat % + Diseases | ||
| Lipids + Δ Age + Diseases | |||||
| -0.051 | 0.100 | -0.080 | |||
| Oxychlordane | -0.063 | -0.078 | |||
| -0.056 | 0.072 | -0.086 | Lipids | ||
| -0.057 | 0.068 | -0.098 | Lipids + Δ Age | ||
| -0.043 | 0.178 | -0.074 | Lipids + Body Fat % | ||
| -0.043 | 0.176 | -0.075 | Lipids+ Δ Age + Body Fat % | ||
| -0.041 | 0.201 | -0.062 | Lipids+ Δ Age + Body Fat % + Diseases | ||
| Lipids + Δ Age + Diseases | |||||
| -0.056 | 0.073 | -0.079 | |||
| Trans-nonachlor | -0.083 | -0.090 | |||
| -0.070 | -0.095 | Lipids | |||
| -0.072 | -0.098 | Lipids + Δ Age | |||
| -0.055 | 0.081 | -0.080 | Lipids + Body Fat % | ||
| -0.056 | 0.078 | -0.082 | Lipids+ Δ Age + Body Fat % | ||
| -0.053 | 0.094 | -0.068 | Lipids+ Δ Age + Body Fat % + Diseases | ||
| Lipids + Δ Age + Diseases | |||||
| -0.071 | -0.088 | ||||
| PCB 153 | -0.064 | -0.090 | |||
| -0.046 | 0.140 | -0.081 | Lipids | ||
| -0.049 | 0.117 | -0.086 | Lipids + Δ Age | ||
| -0.029 | 0.357 | -0.067 | Lipids + Body Fat % | ||
| -0.032 | 0.318 | -0.071 | Lipids+ Δ Age + Body Fat % | ||
| -0.038 | 0.384 | -0.058 | 0.065 | Lipids+ Δ Age + Body Fat % + Diseases | |
| Lipids + Δ Age + Diseases | |||||
| -0.047 | 0.128 | -0.077 | |||
| p,p'-DDE | 0.009 | 0.766 | -0.030 | 0.325 | |
| BDE 47 | 0.027 | 0.718 | -0.013 | 0.681 | |
| BDE 153 | -0.019 | 0.807 | -0.016 | 0.608 | |
| Cumulative POPs | -0.076 | 0.088 | |||
| levels | -0.064 | -0.093 | Lipids | ||
| -0.066 | -0.096 | Lipids + Δ Age | |||
| -0.049 | 0.120 | -0.076 | Lipids + Body Fat % | ||
| -0.050 | 0.112 | -0.078 | Lipids+ Δ Age + Body Fat % | ||
| -0.047 | 0.134 | -0.066 | Lipids+ Δ Age + Body Fat % + Diseases | ||
| Lipids + Δ Age + Diseases | |||||
| -0.066 | -0.089 | ||||
| Oxychlordane | -0.063 | -0.090 | |||
| -0.051 | 0.097 | -0.097 | Lipids | ||
| -0.052 | 0.093 | -0.098 | Lipids + Δ Age | ||
| -0.040 | 0.201 | -0.087 | Lipids + Body Fat % | ||
| -0.040 | 0.202 | -0.087 | Lipids+ Δ Age + Body Fat % | ||
| -0.038 | 0.228 | -0.076 | Lipids+ Δ Age + Body Fat % + Diseases | ||
| Lipids + Δ Age + Diseases | |||||
| -0.051 | 0.098 | ||||
| Trans-nonachlor | -0.084 | 0.092 | |||
| -0.079 | -0.106 | Lipids | |||
| -0.080 | -0.108 | Lipids + Δ Age | |||
| -0.065 | -0.093 | Lipids + Body Fat % | |||
| -0.065 | -0.095 | Lipids+ Δ Age + Body Fat % | |||
| -0.063 | -0.083 | Lipids+ Δ Age + Body Fat % + Diseases | |||
| Lipids + Δ Age + Diseases | |||||
| -0.080 | -0.101 | ||||
| PCB 153 | -0.066 | -0.100 | |||
| -0.050 | 0.106 | -0.097 | Lipids | ||
| -0.063 | 0.087 | -0.103 | Lipids + Δ Age | ||
| -0.032 | 0.311 | -0.084 | Lipids + Body Fat % | ||
| -0.035 | 0.273 | -0.088 | Lipids+ Δ Age + Body Fat % | ||
| -0.032 | 0.297 | -0.078 | Lipids+ Δ Age + Body Fat % + Diseases | ||
| Lipids + Δ Age + Diseases | |||||
| -0.054 | 0.085 | -0.097 | |||
| p,p'-DDE | 0.001 | 0.981 | -0.037 | 0.224 | |
| BDE 47 | 0.026 | 0.397 | -0.014 | 0.638 | |
| BDE 153 | -0.011 | 0.727 | 0.009 | 0.769 | |
Cumulative refers to the sum of the 3 POPs showing significant relationships with telomere length (oxychlordane, trans-nonachlor, PBC 153); multivariate regression analyses (right column) were performed only when a significant relationship was observed in univariate analyses; lipids refer to the sum of total cholesterol and triglycerides serum concentrations at the time of POPs measurements, Δ Age refers to the interval occurring between the baseline and follow-up visit; fat percent refers to the assessment of body composition done at the time of POPs measurements; significant p values are in bold font.
Figure 3.Baseline measurements of body fat percentage ( Comparisons are adjusted for total serum cholesterol and triglycerides, age (all) and fat % (glucose and CRP). Categories 1 to 4 correspond to quartiles. Categories in men and women are calculated based on serum POPs levels within each sex-group. ***p≤0.001, vs all other categories, ‡p=0.059, 0.042 vs categories 1 and 2, respectively, and #p=0.005, 0.040, 0.069 vs category 1, 2 and 3 respectively.
Figure 2.Telomere length at the final visit, in relation to serum POPs concentrations as measured at baseline. The population is stratified based on quartile categories of each POP in men (A) and women (B). Categories in men and women are calculated based on serum wet-weight POPs levels within each sex-group. Analysis is adjusted for total serum cholesterol and triglycerides levels. *p≤0.05.